Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1932296816658055 http://scihub22266oqcxt.onion/10.1177/1932296816658055 C5375067!5375067!27378794     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Diabetes+Sci+Technol 2017 ; 11 (1): 148-56 Nephropedia Template TP {{tp|p=27378794|t=2017. Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin |pdf=|usr=}}{{27378794}} gab.com Text Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin JO: J Diabetes Sci Technol http://www.kidney.de/pget.php?&tw=1&pmid=27378794 #FOAvip Advances in insulin treatment options over recent decades have markedly improved the management of diabetes. Despite this, glycemic control remains suboptimal in many people with diabetes. Although postprandial glucose control has been improved with the development of subcutaneously injected rapid-acting insulin analogs, currently available insulins are not able to fully mimic the physiological time?action profile of endogenously secreted insulin after a meal. The delayed onset of metabolic action and prolonged period of effect induce the risk of postprandial hyperglycemia and late postprandial hypoglycemia. A number of alternative routes of insulin administration have been investigated over time in an attempt to overcome the limitations associated with subcutaneous administration and to provide an improved time?action insulin profile more closely simulating physiological prandial insulin release. Among these, pulmonary insulin delivery has shown the most promise. Technosphere® Inhaled Insulin (TI) is a rapid-acting inhaled human insulin recently approved by the FDA for prandial insulin therapy. In this article we discuss the pharmacokinetic and pharmacodynamic properties of TI, and, based on key studies performed during its clinical development, the implications for improved postprandial glucose control. Twit Text FOAVip Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin ????J Diabetes Sci Technol http://www.kidney.de/pget.php?&tw=1&pmid=27378794 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27378794 #FOAvip English Wikipedia <ref>{{Cite pmid|27378794}}</ref> Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin #MMPMID27378794 Heinemann L; Baughman R; Boss A; Hompesch M J Diabetes Sci Technol 2017[Jan]; 11 (1): 148-56 PMID27378794show ga Advances in insulin treatment options over recent decades have markedly improved the management of diabetes. Despite this, glycemic control remains suboptimal in many people with diabetes. Although postprandial glucose control has been improved with the development of subcutaneously injected rapid-acting insulin analogs, currently available insulins are not able to fully mimic the physiological time?action profile of endogenously secreted insulin after a meal. The delayed onset of metabolic action and prolonged period of effect induce the risk of postprandial hyperglycemia and late postprandial hypoglycemia. A number of alternative routes of insulin administration have been investigated over time in an attempt to overcome the limitations associated with subcutaneous administration and to provide an improved time?action insulin profile more closely simulating physiological prandial insulin release. Among these, pulmonary insulin delivery has shown the most promise. Technosphere® Inhaled Insulin (TI) is a rapid-acting inhaled human insulin recently approved by the FDA for prandial insulin therapy. In this article we discuss the pharmacokinetic and pharmacodynamic properties of TI, and, based on key studies performed during its clinical development, the implications for improved postprandial glucose control. äPharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insu(epmc).pdf DeepDyve Pubget Overpricing